scholarly journals Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer

2006 ◽  
Vol 120 (3) ◽  
pp. 656-663 ◽  
Author(s):  
Martha L. Slattery ◽  
Karen Curtin ◽  
Carol Sweeney ◽  
Theodore R. Levin ◽  
John Potter ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cpg Island ◽  
Lifestyle Factor ◽  
Cpg Island Methylator Phenotype ◽  
Braf Mutations ◽  
Methylator Phenotype ◽  
Diet And Lifestyle

scholarly journals Association of Smoking, CpG Island Methylator Phenotype, and V600E BRAF Mutations in Colon Cancer

2006 ◽  
Vol 98 (23) ◽  
pp. 1731-1738 ◽  
Author(s):  
Wade S. Samowitz ◽  
Hans Albertsen ◽  
Carol Sweeney ◽  
Jennifer Herrick ◽  
Bette J. Caan ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cpg Island ◽  
Cpg Island Methylator Phenotype ◽  
Braf Mutations ◽  
Methylator Phenotype

scholarly journals MSH6 G39E polymorphism and CpG island methylator phenotype in colon cancer

2009 ◽  
Vol 48 (11) ◽  
pp. 989-994 ◽  
Author(s):  
Karen Curtin ◽  
Wade S. Samowitz ◽  
Roger K. Wolff ◽  
Bette J. Caan ◽  
Cornelia M. Ulrich ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cpg Island ◽  
Cpg Island Methylator Phenotype ◽  
Methylator Phenotype

scholarly journals The Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer

Gut and Liver ◽  
2015 ◽  
Vol 9 (2) ◽  
pp. 202-207 ◽  
Author(s):  
Ki Joo Kang ◽  
Byung-Hoon Min ◽  
Kyung Ju Ryu ◽  
Kyoung-Mee Kim ◽  
Dong Kyung Chang ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cpg Island ◽  
Survival Outcome ◽  
Cpg Island Methylator Phenotype ◽  
Methylator Phenotype

Evaluation of the CpG island methylator phenotype as a predictive biomarker for adjuvant oxaliplatin-based chemotherapy in colorectal cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 592-592
Author(s):  
Stacey Shiovitz ◽  
Chen Wu ◽  
Ming Yu ◽  
Georgia Gourgioti ◽  
Georgia Raptou ◽  
...  
Keyword(s):  
Treatment Response ◽  
Cpg Island ◽  
Univariate Analysis ◽  
Disease Free Survival ◽  
Predictive Biomarker ◽  
Primary Objective ◽  
Tnm Stage ◽  
Cpg Island Methylator Phenotype ◽  
Braf Mutations ◽  
Methylator Phenotype

592 Background: The CpG island methylator phenotype (CIMP) has previously been shown to be a predictive biomarker for 5-fluorouracil (5-FU)/leucovorin (LV)/irinotecan (IFL) adjuvant chemotherapy in stage III colon cancer patients. It is unknown if CIMP serves as a biomarker for standard-of-care oxaliplatin-based adjuvant therapy. Methods: HE6C05 randomized 441 patients with stage II/III colorectal adenocarcinoma to adjuvant oxaliplatin with either capecitabine (XELOX) or 5-FU/LV (mFOLFOX6) between November 2005 and January 2008. The primary objective was disease-free survival (DFS); overall survival (OS) was a secondary objective. The study closed early due to poor accrual with last follow-up in November 2013. Isolated DNA from 293 tumor samples was used to determine CIMP status based on methylation patterns at the CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1 loci. Cox univariate and multivariate models were used to assess the effects of CIMP on DFS and OS, accounting for interactions with TNM stage; site (right vs. left); KRAS, BRAF, and mismatch repair (MMR) status; tumor T-cell ratio (CD3/CD8); and treatment arm. Results: Of the tumor samples available for CIMP analysis, 28 (9.6%) were CIMP-positive. The CIMP-positive tumors were more likely to be right-sided and have BRAF mutations (chi-square, p<0.001). In the univariate analysis, no significant differences in DFS or OS were observed between individuals with CIMP-positive vs. negative tumors (OS hazard ratio 1.27, Wald’s p=0.55). In addition, CIMP had no predictive value for response to the treatments administered in the two arms of the trial (XELOX vs. mFOLFOX6). In the multivariate model, only TNM stage and primary site were associated with survival outcome (Wald’s p=0.0002 and p=0.006, respectively); CIMP did not improve treatment response prediction. Conclusions: In this exploratory analysis, unlike what we have seen with IFL, CIMP does not appear to serve as a predictive biomarker for treatment response to oxaliplatin-based therapy. CIMP analysis in an irinotecan vs. oxaliplatin trial may offer additional insight.

scholarly journals CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

Gut ◽  
2008 ◽  
Vol 58 (1) ◽  
pp. 90-96 ◽  
Author(s):  
S. Ogino ◽  
K. Nosho ◽  
G. J Kirkner ◽  
T. Kawasaki ◽  
J. A Meyerhardt ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Outcome ◽  
Microsatellite Instability ◽  
Braf Mutation ◽  
Cpg Island ◽  
Cpg Island Methylator Phenotype ◽  
Methylator Phenotype

Evaluation of a Large, Population-Based Sample Supports a CpG Island Methylator Phenotype in Colon Cancer

2005 ◽  
Vol 129 (3) ◽  
pp. 837-845 ◽  
Author(s):  
Wade S. Samowitz ◽  
Hans Albertsen ◽  
Jennifer Herrick ◽  
Theodore R. Levin ◽  
Carol Sweeney ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cpg Island ◽  
Large Population ◽  
Population Based ◽  
Cpg Island Methylator Phenotype ◽  
Methylator Phenotype

scholarly journals Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet

2007 ◽  
Vol 28 (8) ◽  
pp. 1672-1679 ◽  
Author(s):  
Karen Curtin ◽  
Martha L. Slattery ◽  
Cornelia M. Ulrich ◽  
Jeannette Bigler ◽  
Theodore R. Levin ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Genetic Polymorphisms ◽  
Carbon Metabolism ◽  
Cpg Island ◽  
Cpg Island Methylator Phenotype ◽  
One Carbon Metabolism ◽  
Methylator Phenotype
Sign in / Sign up

Export Citation Format

Share Document